Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metazocine SCHEMBL13353229 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL21994208 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL1649365 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL12049577 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL29387774 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| Metazocine SCHEMBL26347 | 1.00 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL15866689 | 0.92 | SIGMAR1 (0.85) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12267534 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12324824 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 | |
| SCHEMBL12716235 | 0.84 | SIGMAR1 (0.73) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932349-B2 | 8-carboxamido-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| US-20120302591-A1 | METHODS OF USING 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2012-11-29 | — | — | US | disclosed |
| US-8252929-B2 | 8-carboxamido-2,6-methano-3-benzazocines | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110306603-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011137331-A2 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES LLC (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011119605-A2 | CARBOXAMIDE BIOSIOSTERES OF OPIATES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2011-09-29 | — | — | WO | disclosed |
| US-8026252-B2 | Large substituent, non-phenolic opioids and methods of use thereof | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110230511-A1 | CARBOXAMIDE BIOISOSTERES OF OPIATES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110207763-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2266959-A1 | 8-carboxamido-substituted-2, 6-methano-3-benzazocines and 3-carboxamido-substituted morphanes as opioid receptor binding agents | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100190817-A1 | LARGE SUBSTITUENT, NON-PHENOLIC AMINE OPIOIDS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100130512-A1 | FUSED-RING HETEROCYCLE OPIOIDS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20090247562-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009023567-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2007014137-A2 | 8-CARBOXAMIDO-SUBSTITUTED-2 , 6-METHANO-3-BENZAZOCINES AND 3 - CARBOXAMIDO- SUBSTITUTED MORPHANES AS OPIOID RECEPTOR BINDING AGENTS | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247562-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20110306603-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20120302591-A1 | METHODS OF USING 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | HRH4, HRH3, HRH2 | OPRM1 13/4885OPRD1 86/4885OPRK1 60/4885 |
| US-20100190817-A1 | LARGE SUBSTITUENT, NON-PHENOLIC AMINE OPIOIDS | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20100130512-A1 | FUSED-RING HETEROCYCLE OPIOIDS | OPRK1, OPRD1, OPRL1 | OPRM1 4/4885OPRD1 2/4885OPRK1 1/4885 |
| US-20170217977-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | HRH4, HRH2, HRH3 | OPRM1 8/4885OPRD1 38/4885OPRK1 27/4885 |
| US-20110207763-A1 | 8-CARBOXAMIDO-2,6-METHANO-3-BENZAZOCINES | HRH4, HRH2, HRH3 | OPRM1 8/4885OPRD1 38/4885OPRK1 27/4885 |
| US-20110230511-A1 | CARBOXAMIDE BIOISOSTERES OF OPIATES | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRD1 2/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.